ESNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Essent Group Ltd (ESNT) is not a strong buy at the moment given the lack of positive catalysts, bearish technical indicators, insider selling trends, and declining financial performance. While the stock may appeal to long-term investors due to its strong balance sheet and conservative estimates, the current market conditions and technical setup do not present an optimal entry point for a beginner investor with a long-term strategy.
The technical indicators for ESNT are bearish. The MACD is below 0 and negatively contracting, indicating weak momentum. The RSI is neutral at 34.836, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 57.083), with resistance at R1: 59.264. Overall, the technical setup suggests a lack of upward momentum.
Analysts from firms like Roth Capital and BofA maintain a Buy rating with price targets of $75 and $68, respectively, citing the company's strong balance sheet and conservative estimates. Additionally, the EPS has increased by 1.27% YoY, which is a small but positive sign.
Insiders are selling, with a 192.05% increase in selling activity over the past month. Financial performance in Q4 2025 showed a decline in revenue (-0.83% YoY) and net income (-7.69% YoY). There are no recent news catalysts, and hedge funds are neutral on the stock. The stock trend analysis indicates a potential for slight declines in the short term (-0.63% next day, -0.96% next week, -0.37% next month).
In Q4 2025, revenue dropped by -0.83% YoY to $312.4M, and net income declined by -7.69% YoY to $154.98M. However, EPS increased slightly by 1.27% YoY to 1.6, and gross margin remained flat. Overall, the financial performance shows a mixed picture with declining growth trends.
Analyst ratings are mixed. UBS and Barclays lowered their price targets to $63, maintaining Neutral and Equal Weight ratings. BofA and Roth Capital raised their price targets to $68 and $75, respectively, with Buy ratings. Goldman Sachs raised its target to $70 but kept a Neutral rating. Analysts highlight credit risk and macro concerns but acknowledge the company's strong balance sheet and potential for loan growth in 2026.
